S&P 500   4,275.45 (+0.04%)
DOW   33,584.12 (-0.10%)
QQQ   355.60 (+0.39%)
AAPL   171.23 (-0.42%)
MSFT   311.66 (-0.15%)
META   300.05 (+0.36%)
GOOGL   129.14 (+0.44%)
AMZN   125.78 (-0.16%)
TSLA   243.65 (-0.19%)
NVDA   422.41 (+0.79%)
NIO   8.39 (-0.24%)
BABA   86.32 (+0.48%)
AMD   97.48 (+1.58%)
T   14.93 (-0.60%)
F   12.40 (-0.24%)
MU   68.06 (+0.18%)
CGC   0.95 (+3.42%)
GE   110.67 (+0.67%)
DIS   80.52 (+0.59%)
AMC   8.01 (+1.26%)
PFE   32.24 (-0.49%)
PYPL   59.30 (+0.63%)
NFLX   381.38 (+0.56%)
S&P 500   4,275.45 (+0.04%)
DOW   33,584.12 (-0.10%)
QQQ   355.60 (+0.39%)
AAPL   171.23 (-0.42%)
MSFT   311.66 (-0.15%)
META   300.05 (+0.36%)
GOOGL   129.14 (+0.44%)
AMZN   125.78 (-0.16%)
TSLA   243.65 (-0.19%)
NVDA   422.41 (+0.79%)
NIO   8.39 (-0.24%)
BABA   86.32 (+0.48%)
AMD   97.48 (+1.58%)
T   14.93 (-0.60%)
F   12.40 (-0.24%)
MU   68.06 (+0.18%)
CGC   0.95 (+3.42%)
GE   110.67 (+0.67%)
DIS   80.52 (+0.59%)
AMC   8.01 (+1.26%)
PFE   32.24 (-0.49%)
PYPL   59.30 (+0.63%)
NFLX   381.38 (+0.56%)
S&P 500   4,275.45 (+0.04%)
DOW   33,584.12 (-0.10%)
QQQ   355.60 (+0.39%)
AAPL   171.23 (-0.42%)
MSFT   311.66 (-0.15%)
META   300.05 (+0.36%)
GOOGL   129.14 (+0.44%)
AMZN   125.78 (-0.16%)
TSLA   243.65 (-0.19%)
NVDA   422.41 (+0.79%)
NIO   8.39 (-0.24%)
BABA   86.32 (+0.48%)
AMD   97.48 (+1.58%)
T   14.93 (-0.60%)
F   12.40 (-0.24%)
MU   68.06 (+0.18%)
CGC   0.95 (+3.42%)
GE   110.67 (+0.67%)
DIS   80.52 (+0.59%)
AMC   8.01 (+1.26%)
PFE   32.24 (-0.49%)
PYPL   59.30 (+0.63%)
NFLX   381.38 (+0.56%)
S&P 500   4,275.45 (+0.04%)
DOW   33,584.12 (-0.10%)
QQQ   355.60 (+0.39%)
AAPL   171.23 (-0.42%)
MSFT   311.66 (-0.15%)
META   300.05 (+0.36%)
GOOGL   129.14 (+0.44%)
AMZN   125.78 (-0.16%)
TSLA   243.65 (-0.19%)
NVDA   422.41 (+0.79%)
NIO   8.39 (-0.24%)
BABA   86.32 (+0.48%)
AMD   97.48 (+1.58%)
T   14.93 (-0.60%)
F   12.40 (-0.24%)
MU   68.06 (+0.18%)
CGC   0.95 (+3.42%)
GE   110.67 (+0.67%)
DIS   80.52 (+0.59%)
AMC   8.01 (+1.26%)
PFE   32.24 (-0.49%)
PYPL   59.30 (+0.63%)
NFLX   381.38 (+0.56%)
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Forecast, Price & News

Notice: Trading of Brainstorm Cell Therapeutics halted at 06:55 AM EST due to "News pending".
$0.42
+0.03 (+8.27%)
(As of 08:02 AM ET)
Compare
Today's Range
$0.42
▼
$0.42
50-Day Range
$0.39
▼
$1.84
52-Week Range
$0.39
▼
$4.56
Volume
28,762 shs
Average Volume
347,698 shs
Market Capitalization
$19.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Brainstorm Cell Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,256.3% Upside
$10.00 Price Target
Short Interest
Bearish
9.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
-0.24mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$20,355 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to ($0.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

471st out of 963 stocks

Biological Products, Except Diagnostic Industry

72nd out of 159 stocks

See Top Rated MarketRank™ Stocks Here

BCLI stock logo

About Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Price History

BCLI Stock News Headlines

September 27, 2023 | finanznachrichten.de
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Stock Trading Halted Today
September 27, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Stock Trading Halted Today
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 26, 2023 | finance.yahoo.com
BCLI: Public Support for NurOwn® from Prominent ALS Specialists…
September 25, 2023 | proactiveinvestors.com
BrainStorm Cell plummets after FDA raises doubts over ALS therapy
September 25, 2023 | msn.com
Why Is Neurodegenerative Disease-Focused Brainstorm Cell Therapeutics Stock Plunging Today?
September 25, 2023 | reuters.com
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
September 25, 2023 | msn.com
Brainstorm falls as FDA posts briefing docs on ALS therapy
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 15, 2023 | msn.com
BrainStorm Cell Therapeutics; I Anticipate A Positive AdCom But There Are Major Risks
August 18, 2023 | finance.yahoo.com
BCLI: Preparing for AdCom on September 27, 2023…
August 15, 2023 | finance.yahoo.com
Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call
August 14, 2023 | finanznachrichten.de
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 8, 2023 | finance.yahoo.com
BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update
July 17, 2023 | finance.yahoo.com
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
July 12, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
July 7, 2023 | msn.com
BrainStorm Cell Therapeutics Shares Fall After Updated Biomarker Data From Lead Cell Therapy Candidate
July 7, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration
June 20, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
June 16, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference
June 6, 2023 | msn.com
FDA panel to review BrainStorm's NurOwn therapy for ALS
June 6, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023
May 24, 2023 | msn.com
Brainstorm Cell COO Setboun to leave company - filing
May 23, 2023 | finance.yahoo.com
BCLI: Awaiting Adcom Date for NurOwn®…
May 19, 2023 | finance.yahoo.com
BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit
May 18, 2023 | finance.yahoo.com
While institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are its largest shareholders with 59% ownership
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCLI
CUSIP
N/A
CIK
1137883
Web
www.brainstorm-cell.com
Phone
(201) 488-0460
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+2,451.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.74)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,280,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-6,929.48%
Return on Assets
-309.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.16
Quick Ratio
0.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.08) per share
Price / Book
-4.90

Miscellaneous

Outstanding Shares
45,020,000
Free Float
40,379,000
Market Cap
$17.65 million
Optionable
Optionable
Beta
-0.51
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Chaim Lebovits (Age 52)
    Pres & CEO
    Comp: $990.42k
  • Dr. Stacy R. Lindborg Ph.D. (Age 52)
    Co-Chief Exec. Officer
    Comp: $708.39k
  • Dr. Irit Arbel DSc (Age 63)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Mr. Uri Yablonka (Age 46)
    Exec. VP, Chief Bus. Officer, Sec. & Director
  • Ms. Alla Patlis CPA (Age 36)
    M.B.A., Controller & Interim CFO
  • Dr. Yael Gothelf
    VP of Scientific & Regulatory Affairs
  • Ms. Antal Pearl-Lendner
    VP & Chief Legal Counsel
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Sr. VP of Patient Advocacy & Gov. Affairs
  • Mr. William K. White
    Sr. VP & Head of Market Access and Pricing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BCLI Stock - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCLI shares.
View BCLI analyst ratings or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for Brainstorm Cell Therapeutics' shares. Their BCLI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 2,451.0% from the stock's current price.
View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2023?

Brainstorm Cell Therapeutics' stock was trading at $1.64 on January 1st, 2023. Since then, BCLI stock has decreased by 76.1% and is now trading at $0.3920.
View the best growth stocks for 2023 here.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our BCLI earnings forecast.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.12.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.23%), Renaissance Technologies LLC (0.52%), Worth Venture Partners LLC (0.45%), Citadel Advisors LLC (0.00%), Marshall Wace LLP (0.17%) and LPL Financial LLC (0.11%).
View institutional ownership trends.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $0.39.

How much money does Brainstorm Cell Therapeutics make?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $17.65 million. The biotechnology company earns $-24,280,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.

This page (NASDAQ:BCLI) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -